You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAllylestrenol
Accession NumberDB01431
TypeSmall Molecule
GroupsApproved
DescriptionA synthetic steroid with progestational activity. [PubChem]
Structure
Thumb
Synonyms
Allyl estrenol
Allyloestrenol
Perselin
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
GestaninNot Available
GestanolNot Available
GestanonNot Available
GestinNot Available
GestrenolNot Available
MaintaineNot Available
OragestonNot Available
ProfarNot Available
TurinalNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIII47VB5DZ8O
CAS number432-60-0
WeightAverage: 300.4782
Monoisotopic: 300.245315646
Chemical FormulaC21H32O
InChI KeyInChIKey=ATXHVCQZZJYMCF-XUDSTZEESA-N
InChI
InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1
IUPAC Name
(1S,2R,10R,11S,14R,15S)-15-methyl-14-(prop-2-en-1-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-ol
SMILES
[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as estrane steroids. These are steroids with a structure based on the estrane skeleton.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassEstrane steroids
Direct ParentEstrane steroids
Alternative Parents
Substituents
  • 17-hydroxysteroid
  • Hydroxysteroid
  • Estrane-skeleton
  • Delta-4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Hydrocarbon derivative
  • Organooxygen compound
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
  • C21 steroids (gluco/mineralocorticoids, progestogens) and derivatives (C12811 )
  • Estrane and derivatives (C12811 )
  • C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030125 )
Pharmacology
IndicationAllylestrenol was designed to be used for miscarriage prevention, prevention of premature labour and has been investigated for possible use in men for treatment for benign prostatic hyperplasia.
PharmacodynamicsAllylestrenol is a progestogen structurally related to progesterone that has been given in threatened and recurrent miscarriage, and to prevent premature labour. However, with the exception of proven progesterone deficiency, such use is no longer recommended. In threatened miscarriage in progesterone-deficient women a suggested dose is 5 mg three times daily by mouth for 5 to 7 days.
Mechanism of actionAllylestrenol is similar in structure and function to progesterone. Progesterone shares the pharmacological actions of the progestins. Progesterone binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like Progesterone will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. In women who have adequate endogenous estrogen, progesterone transforms a proliferative endometrium into a secretory one. Progesterone is essential for the development of decidual tissue and is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo has been implanted, progesterone acts to maintain the pregnancy. Progesterone also stimulates the growth of mammary alveolar tissue and relaxes uterine smooth muscle. It has little estrogenic and androgenic activity.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationThe glucuronide and sulfate conjugates of pregnanediol and pregnanolone are excreted in the urine and bile. Progesterone metabolites which are excreted in the bile may undergo enterohepatic recycling or may be excreted in the feces. Progesterone metabolites are excreted mainly by the kidneys.
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9817
Caco-2 permeable+0.8469
P-glycoprotein substrateSubstrate0.6615
P-glycoprotein inhibitor IInhibitor0.5781
P-glycoprotein inhibitor IINon-inhibitor0.795
Renal organic cation transporterNon-inhibitor0.6625
CYP450 2C9 substrateNon-substrate0.807
CYP450 2D6 substrateNon-substrate0.9046
CYP450 3A4 substrateSubstrate0.6941
CYP450 1A2 substrateNon-inhibitor0.8345
CYP450 2C9 inhibitorNon-inhibitor0.8006
CYP450 2D6 inhibitorNon-inhibitor0.9427
CYP450 2C19 inhibitorInhibitor0.5498
CYP450 3A4 inhibitorNon-inhibitor0.8408
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6449
Ames testNon AMES toxic0.936
CarcinogenicityNon-carcinogens0.9458
BiodegradationNot ready biodegradable0.9828
Rat acute toxicity2.4200 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6669
hERG inhibition (predictor II)Non-inhibitor0.7541
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point80 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.000558 mg/mLALOGPS
logP5.14ALOGPS
logP4.83ChemAxon
logS-5.7ALOGPS
pKa (Strongest Basic)-0.17ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area20.23 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity93.14 m3·mol-1ChemAxon
Polarizability37.17 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesG03DC01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Allylestrenol.
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Allylestrenol.
AmiodaroneThe metabolism of Allylestrenol can be decreased when combined with Amiodarone.
AncrodThe therapeutic efficacy of Ancrod can be decreased when used in combination with Allylestrenol.
Antithrombin III humanThe therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Allylestrenol.
ApixabanThe therapeutic efficacy of Apixaban can be decreased when used in combination with Allylestrenol.
AprepitantThe serum concentration of Allylestrenol can be increased when it is combined with Aprepitant.
ArdeparinThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Allylestrenol.
ArgatrobanThe therapeutic efficacy of Argatroban can be decreased when used in combination with Allylestrenol.
AtazanavirThe metabolism of Allylestrenol can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Allylestrenol can be decreased when combined with Atomoxetine.
BecaplerminThe therapeutic efficacy of Becaplermin can be decreased when used in combination with Allylestrenol.
BexaroteneThe serum concentration of Allylestrenol can be decreased when it is combined with Bexarotene.
BivalirudinThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Allylestrenol.
BoceprevirThe metabolism of Allylestrenol can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Allylestrenol can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Allylestrenol can be decreased when it is combined with Bosentan.
C1 Esterase Inhibitor (Human)Allylestrenol may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).
C1 Esterase Inhibitor (Recombinant)Allylestrenol may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).
CarbamazepineThe metabolism of Allylestrenol can be increased when combined with Carbamazepine.
CeritinibThe serum concentration of Allylestrenol can be increased when it is combined with Ceritinib.
CertoparinThe therapeutic efficacy of Certoparin can be decreased when used in combination with Allylestrenol.
Citric AcidThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Allylestrenol.
ClarithromycinThe metabolism of Allylestrenol can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Allylestrenol can be decreased when combined with Clemastine.
ClotrimazoleThe metabolism of Allylestrenol can be decreased when combined with Clotrimazole.
CobicistatThe metabolism of Allylestrenol can be decreased when combined with Cobicistat.
ConivaptanThe serum concentration of Allylestrenol can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Allylestrenol can be decreased when combined with Crizotinib.
CyclosporineThe metabolism of Allylestrenol can be decreased when combined with Cyclosporine.
Dabigatran etexilateThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Allylestrenol.
DabrafenibThe serum concentration of Allylestrenol can be decreased when it is combined with Dabrafenib.
DalteparinThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Allylestrenol.
DanaparoidThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Allylestrenol.
DarunavirThe metabolism of Allylestrenol can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Allylestrenol can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Allylestrenol can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Allylestrenol can be decreased when combined with Delavirdine.
DesirudinThe therapeutic efficacy of Desirudin can be decreased when used in combination with Allylestrenol.
DexamethasoneThe serum concentration of Allylestrenol can be decreased when it is combined with Dexamethasone.
DextranThe therapeutic efficacy of Dextran can be decreased when used in combination with Allylestrenol.
Dextran 40The therapeutic efficacy of Dextran 40 can be decreased when used in combination with Allylestrenol.
Dextran 70The therapeutic efficacy of Dextran 70 can be decreased when used in combination with Allylestrenol.
Dextran 75The therapeutic efficacy of Dextran 75 can be decreased when used in combination with Allylestrenol.
DicoumarolThe therapeutic efficacy of Dicoumarol can be decreased when used in combination with Allylestrenol.
DihydroergotamineThe metabolism of Allylestrenol can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Allylestrenol can be decreased when combined with Diltiazem.
DoxycyclineThe metabolism of Allylestrenol can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Allylestrenol can be decreased when combined with Dronedarone.
Edetic AcidThe therapeutic efficacy of Edetic Acid can be decreased when used in combination with Allylestrenol.
EdoxabanThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Allylestrenol.
EfavirenzThe serum concentration of Allylestrenol can be decreased when it is combined with Efavirenz.
EnoxaparinThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Allylestrenol.
EnzalutamideThe serum concentration of Allylestrenol can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Allylestrenol can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Allylestrenol can be decreased when it is combined with Eslicarbazepine acetate.
Ethyl biscoumacetateThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Allylestrenol.
EtravirineThe serum concentration of Allylestrenol can be decreased when it is combined with Etravirine.
FluconazoleThe metabolism of Allylestrenol can be decreased when combined with Fluconazole.
FluvoxamineThe metabolism of Allylestrenol can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumThe therapeutic efficacy of Fondaparinux sodium can be decreased when used in combination with Allylestrenol.
FosamprenavirThe metabolism of Allylestrenol can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Allylestrenol can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Allylestrenol can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Allylestrenol can be increased when it is combined with Fusidic Acid.
HeparinThe therapeutic efficacy of Heparin can be decreased when used in combination with Allylestrenol.
HirulogThe therapeutic efficacy of Hirulog can be decreased when used in combination with Allylestrenol.
IdelalisibThe serum concentration of Allylestrenol can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Allylestrenol can be decreased when combined with Imatinib.
IndinavirThe metabolism of Allylestrenol can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Allylestrenol can be decreased when combined with Isavuconazonium.
IsradipineThe metabolism of Allylestrenol can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Allylestrenol can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Allylestrenol can be increased when it is combined with Ivacaftor.
KetoconazoleThe metabolism of Allylestrenol can be decreased when combined with Ketoconazole.
LepirudinThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Allylestrenol.
LopinavirThe metabolism of Allylestrenol can be decreased when combined with Lopinavir.
LovastatinThe metabolism of Allylestrenol can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Allylestrenol can be increased when it is combined with Luliconazole.
MifepristoneThe metabolism of Allylestrenol can be decreased when combined with Mifepristone.
MitotaneThe serum concentration of Allylestrenol can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Allylestrenol can be decreased when it is combined with Modafinil.
NadroparinThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Allylestrenol.
NafcillinThe serum concentration of Allylestrenol can be decreased when it is combined with Nafcillin.
NefazodoneThe metabolism of Allylestrenol can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Allylestrenol can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Allylestrenol can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Allylestrenol can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Allylestrenol can be decreased when combined with Nilotinib.
OlaparibThe metabolism of Allylestrenol can be decreased when combined with Olaparib.
OsimertinibThe serum concentration of Allylestrenol can be increased when it is combined with Osimertinib.
OtamixabanThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Allylestrenol.
PalbociclibThe serum concentration of Allylestrenol can be increased when it is combined with Palbociclib.
PentobarbitalThe metabolism of Allylestrenol can be increased when combined with Pentobarbital.
Pentosan PolysulfateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Allylestrenol.
PhenindioneThe therapeutic efficacy of Phenindione can be decreased when used in combination with Allylestrenol.
PhenobarbitalThe metabolism of Allylestrenol can be increased when combined with Phenobarbital.
PhenprocoumonThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Allylestrenol.
PhenytoinThe metabolism of Allylestrenol can be increased when combined with Phenytoin.
PosaconazoleThe metabolism of Allylestrenol can be decreased when combined with Posaconazole.
PrimidoneThe metabolism of Allylestrenol can be increased when combined with Primidone.
Protein CThe therapeutic efficacy of Protein C can be decreased when used in combination with Allylestrenol.
ProtocatechualdehydeThe therapeutic efficacy of Protocatechualdehyde can be decreased when used in combination with Allylestrenol.
RanolazineThe metabolism of Allylestrenol can be decreased when combined with Ranolazine.
ReviparinThe therapeutic efficacy of Reviparin can be decreased when used in combination with Allylestrenol.
RifabutinThe metabolism of Allylestrenol can be increased when combined with Rifabutin.
RifampicinThe metabolism of Allylestrenol can be increased when combined with Rifampicin.
RifapentineThe metabolism of Allylestrenol can be increased when combined with Rifapentine.
RitonavirThe metabolism of Allylestrenol can be decreased when combined with Ritonavir.
RivaroxabanThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Allylestrenol.
SaquinavirThe metabolism of Allylestrenol can be decreased when combined with Saquinavir.
SildenafilThe metabolism of Allylestrenol can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Allylestrenol can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Allylestrenol can be increased when it is combined with Simeprevir.
St. John's WortThe serum concentration of Allylestrenol can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Allylestrenol can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Allylestrenol can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Allylestrenol.
TelaprevirThe metabolism of Allylestrenol can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Allylestrenol can be decreased when combined with Telithromycin.
TiclopidineThe metabolism of Allylestrenol can be decreased when combined with Ticlopidine.
TocilizumabThe serum concentration of Allylestrenol can be decreased when it is combined with Tocilizumab.
UlipristalThe therapeutic efficacy of Allylestrenol can be decreased when used in combination with Ulipristal.
VenlafaxineThe metabolism of Allylestrenol can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Allylestrenol can be decreased when combined with Verapamil.
VoriconazoleThe metabolism of Allylestrenol can be decreased when combined with Voriconazole.
WarfarinThe therapeutic efficacy of Warfarin can be decreased when used in combination with Allylestrenol.
XimelagatranThe therapeutic efficacy of Ximelagatran can be decreased when used in combination with Allylestrenol.
ZiprasidoneThe metabolism of Allylestrenol can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor isoform B (PRB) is involved activation of c-SRC/MAPK signaling on hormone stimulation.Isoform A: inactive in stimulating c-Src/MAPK signaling on hormone stimulation.Isoform 4: Increases mitochondrial ...
Gene Name:
PGR
Uniprot ID:
P06401
Molecular Weight:
98979.96 Da
References
  1. Madauss KP, Stewart EL, Williams SP: The evolution of progesterone receptor ligands. Med Res Rev. 2007 May;27(3):374-400. [PubMed:17013809 ]
  2. Gizard F, Robillard R, Gross B, Barbier O, Revillion F, Peyrat JP, Torpier G, Hum DW, Staels B: TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. Mol Cell Biol. 2006 Oct;26(20):7632-44. [PubMed:17015480 ]
  3. Wu HB, Fabian S, Jenab S, Quinones-Jenab V: Progesterone receptors activation after acute cocaine administration. Brain Res. 2006 Dec 18;1126(1):188-92. Epub 2006 Nov 15. [PubMed:17109827 ]
  4. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP: The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol. 2007 Feb;21(2):359-75. Epub 2006 Nov 30. [PubMed:17138644 ]
  5. Tranguch S, Smith DF, Dey SK: Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation. Reprod Biomed Online. 2006 Nov;13(5):651-60. [PubMed:17169175 ]
  6. Bergink EW, Loonen PB, Kloosterboer HJ: Receptor binding of allylestrenol, a progestagen of the 19-nortestosterone series without androgenic properties. J Steroid Biochem. 1985 Aug;23(2):165-8. [PubMed:3928974 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Molecular Weight:
66215.45 Da
References
  1. Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, Hwang ES: Type and duration of exogenous hormone use affects breast cancer histology. Ann Surg Oncol. 2007 Feb;14(2):695-703. Epub 2006 Nov 14. [PubMed:17103262 ]
  2. Lessey BA, Palomino WA, Apparao KB, Young SL, Lininger RA: Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women. Reprod Biol Endocrinol. 2006;4 Suppl 1:S9. [PubMed:17118173 ]
  3. Yuri T, Tsukamoto R, Uehara N, Matsuoka Y, Tsubura A: Effects of different durations of estrogen and progesterone treatment on development of N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats. In Vivo. 2006 Nov-Dec;20(6B):829-36. [PubMed:17203775 ]
  4. Montero Girard G, Vanzulli SI, Cerliani JP, Bottino MC, Bolado J, Vela J, Becu-Villalobos D, Benavides F, Gutkind S, Patel V, Molinolo A, Lanari C: Association of estrogen receptor-alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment. Breast Cancer Res. 2007;9(2):R22. [PubMed:17341305 ]
  5. Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T, Dermime S: Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer. 2007 Aug 15;121(4):751-8. [PubMed:17415709 ]
  6. Csaba G, Gonda AI, Karabelyos C: Contraceptive treatment increases the affinity of uterine estrogen receptor in adult rat: perinatal gestagen treatment changes the reaction. Horm Metab Res. 1996 Jan;28(1):16-9. [PubMed:8820988 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on July 24, 2007 10:58 / Updated on August 17, 2016 12:23